Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials

Two Phase III atopic dermatitis therapy in development by Eli Lilly and Company and Incyte Corporation hit the mark at 16 weeks. The two late-stage studies are part of a five clinical trial study program aimed at determining the safety and efficacy of baricitinib in treating these patients.